Dir, Pres, CEO at Damora Therapeutics, Inc. Buys $252,875 in Stock

Jennifer Jarrett, who serves as Dir, Pres, CEO at Damora Therapeutics, Inc. (DMRA), purchased 12,500 shares of the company's stock, according to a disclosure filed with the U.S. Securities and Exchange Commission.

The transaction was executed at a price of $20.23 per share, for a total value of approximately $252,875.

Insider transactions of this kind are publicly disclosed through Form 4 filings with the SEC, which must generally be submitted within two business days of the trade date.

Purchases by company insiders are one of several signals investors monitor, alongside earnings results and broader sector trends.